Associated Banc Corp Purchases 5,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Associated Banc Corp acquired a new stake of 5,962 Vertex Pharmaceuticals shares in the third quarter, valued at approximately $3.12 million. Institutional investors and hedge funds collectively own 90.96% of Vertex’s stock.
• Vertex reported quarterly revenue of $3.44 billion, up 11.8% year over year and slightly above estimates, but EPS of $4.76 missed the consensus estimate of $4.82.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $596.44. Shares opened at $549.04 and were reported up 3.4%.

Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,962 shares of the pharmaceutical company's stock, valued at approximately $3,117,000.

A number of other hedge funds also recently bought and sold shares of VRTX. BlackRock Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $11,975,849,000. Bank of America Corp DE purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $1,509,651,000. Legal & General Group Plc purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $928,893,000. Bank of New York Mellon Corp acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $830,842,000. Finally, Deutsche Bank AG acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $784,391,000. Institutional investors and hedge funds own 90.96% of the company's stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up 12% year over year and ahead of estimates, with cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributing. The company raised its 2026 revenue outlook, while management highlighted the potential for povetacicept, which faces an FDA decision for IgA nephropathy on November 30. Vertex Q3 2026 earnings call highlights
• Positive Sentiment: Analyst actions have generally been supportive: Barclays raised its price target to $626 and kept an overweight rating, while H.C. Wainwright reiterated Buy and TD Cowen also rated the shares Buy. These endorsements may bolster confidence in Vertex’s growth prospects.
• Neutral Sentiment: Investors are also focused on Vertex’s efforts to expand beyond cystic fibrosis into kidney and rare endocrine diseases—potential future growth drivers, but ones that will take time to establish. Vertex: 3 key takeaways for long-term investors
• Negative Sentiment: Quarterly earnings per share came in below analyst expectations, and acquisition costs weighed on profit. Reports also pointed to lighter-than-hoped-for sales of the pain drug JOURNAVX, contributing to a selloff after the earnings release. Vertex slumps on light pain drug sales

Vertex Pharmaceuticals Stock Up 3.4%

VRTX opened at $549.04 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $406.67 and a 52 week high of $568.67. The firm has a market cap of $139.35 billion, a P/E ratio of 35.33, a PEG ratio of 2.56 and a beta of 0.28. The business's fifty day simple moving average is $522.90 and its 200 day simple moving average is $480.92. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business had revenue of $3.44 billion during the quarter, compared to analysts' expectations of $3.42 billion. During the same period in the prior year, the firm earned $4.80 EPS. Vertex Pharmaceuticals's revenue for the quarter was up 11.8% on a year-over-year basis. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on VRTX shares. Scotiabank lifted their price target on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a "sector outperform" rating in a research report on Tuesday. Rothschild & Co Redburn increased their price objective on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an "outperform" rating in a report on Tuesday. Evercore upped their target price on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an "outperform" rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings raised Vertex Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $596.44.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.